1.Prajapat, M., Shekhar, N., Sarma, P., Avti, P., Singh, S.,
Kaur, H., Bhattacharyya, A., Kumar, S., Sharma, S.,
Prakash, A., & Medhi, B. Virtual screening and molecular
dynamics study of approved drugs as inhibitors of spike
protein S1 domain and ACE2 interaction in SARS-
CoV-2. Journal of Molecular Graphics and Modelling.
2020;101, 107716.
2.Cheung, N. Y. C., Fung, J. L. F., Ng, Y. N. C., Wong,
W. H. S., Chung, C. C. Y., Mak, C. C. Y., & Chung,
B. H. Y. Perception of personalized medicine,
pharmacogenomics, and genetic testing among
undergraduates in Hong Kong. Human Genomics. 2021
; 15(1), 1–12.
3.Mahmutovic, L., Akcesme, B., Durakovic, C.,
Akcesme, F. B., Maric, A., Adilovic, M., Hamad, N.,
Wjst, M., Feeney, O., & Semiz, S. Perceptions of
students in health and molecular life sciences regarding
pharmacogenomics and personalized medicine. Human
Genomics. 2018; 12(1), 1–15.
4.Saud, K., & Syed, W. Knowledge, Attitude and
Perception of University of Ibadan Pharmacy Students
on Veterinary Pharmacy Practice. Nigerian Journal of
Pharmacy. 2022 ; 56(1).
5.Moses III, H., & Martin, J. B. Academic Relationships
With Industry. Jama.2001 ; 285(7), 933.
6.Dhawan, D., & Padh, H. Pharmacogenomics and
personalized medicine for cancer. In Omics for
Personalized Medicine. 2013.
7.Abou Diwan, E., Zeitoun, R. I., Abou Haidar, L.,
Cascorbi, I., & Khoueiry Zgheib, N. Implementation
and obstacles of pharmacogenetics in clinical practice:
An international survey. British Journal of Clinical
Pharmacology. 2019 ; 85(9), 2076–2088.
8.Relling, M. V., & Evans, W. E. Pharmacogenomics in
the clinic. Nature.2015 ; 526(7573), 343–350.
9.Norton, R. Pharmacogenomics: The Search for
Individualized Therapies. In Drug Discovery Today.
2002 ; (Vol. 7, Issue 21).
10.Robert, F., & Pelletier, J. Exploring the Impact of
Single-Nucleotide Polymorphisms on Translation.
Frontiers in Genetics. 2018 ; 9(October), 1–11.
11.Madsen, B. E., Villesen, P., & Wiuf, C. A periodic
pattern of SNPs in the human genome. Genome
Research. 2007 ; 17(10), 1414–1419.
Nashrifa Israt Khanomet al Pers M J23
12.Reisberg, S., Krebs, K., Lepamets, M., Kals, M., Mägi,
R., Metsalu, K., Lauschke, V. M., Vilo, J., & Milani, L.
Translating genotype data of 44,000 biobank participants
into clinical pharmacogenetic recommendations:
challenges and solutions. Genetics in Medicine. 2019 ;
21(6), 1345–1354.
13.Shepherd, G., Mohorn, P., Yacoub, K., & May, D. W.
Décès suite aux effets indésirables rapportés aux États
Unis en utilisant les statistiques de l’état civil entre
1999-2006. Annals of Pharmacotherapy. 2012 ; 46(2),
169–175.
14.Koutsilieri, S., Tzioufa, F., Sismanoglou, D. C.,
& Patrinos, G. P. (2020). Unveiling the guidance
heterogeneity for genome-informed drug treatment
interventions among regulatory bodies and research
consortia. Pharmacological Research. 2020 ; 153,
104590.
15.Kinsella, M., & Monk, C. NIH Public Access. 2012 ;
23(1), 1–7.
16.Burke, W. Clinical validity and clinical utility of
genetic tests. Current Protocols in Human Genetics,
SUPPL. 2009 ; 60, 1–7.
17.Issa, A. M., & Keyserlingk, E. W. Apolipoprotein
E genotyping for pharmacogenetic purposes in
Alzheimer’s disease: Emerging ethical issues. Canadian
Journal of Psychiatry. 2000 ; 45(10), 917–922.
18.Robertson, J. A. Consent and privacy in pharmacogenetic
testing. Nature Genetics. 2001 ; 28(3).
19.Khan, S., Akter, S., Goswami, B., Habib, A.,
Banu, T. A., Barton, C., Osman, E., Samir, S.,
Arjuman, F., Hasan, S., & Hossain, M. Whole
genome mapping and identification of single nucleotide
polymorphisms of four Bangladeshi individuals and
their functional significance. BMC Research Notes.
2021 ; 14(1), 1–6.
20.Ahammad, I., Hossain, M. U., Rahman, A., Chowdhury,
Z. M., Bhattacharjee, A., Das, K. C., Keya, C. A., &
Salimullah, M. Wave-wise comparative genomic study
for revealing the complete scenario and dynamic nature
of COVID-19 pandemic in Bangladesh. PLoS ONE.
2021 ; 16(9 September), 1–21.
21.Akter, S. (n.d.). Genome sequencing and genetic
characterization of 17 SARS-CoV-2 viruses and spike
protein analyses of isolates from Bangladeshi patients.
Research Square. 2021; 1–20.
22.Rahman, M. M., Kader, S. B., & Rizvi, S. M. S.
Molecular characterization of SARS-CoV-2 from
Bangladesh: implications in genetic diversity, possible
origin of the virus, and functional significance of the
mutations, Heliyon. 2021; 7(8), e07866.
23.Swen, J. J., Nijenhuis, M., van Rhenen, M., de Boer-
Veger, N. J., Buunk, A. M., Houwink, E. J. F., Mulder,
H., Rongen, G. A., van Schaik, R. H. N., van der Weide,
J., Wilffert, B., Deneer, V. H. M., & Guchelaar, H. J.
Pharmacogenetic Information in Clinical Guidelines:
The European Perspective. Clinical Pharmacology and
Therapeutics. 2018; 103(5), 795–801.
24.Volpi, S., Bult, C. J., Chisholm, R. L., Deverka, P. A.,
Ginsburg, G. S., Jacob, H. J., Kasapi, M., McLeod,
H. L., Roden, D. M., Williams, M. S., Green, E. D.,
Rodriguez, L. L., Aronson, S., Cavallari, L. H., Denny,
J. C., Dressler, L. G., Johnson, J. A., Klein, T. E., Leeder,
J. S., Relling, M. V. Research Directions in the Clinical
Implementation of Pharmacogenomics: An Overview of
US Programs and Projects. Clinical Pharmacology and
Therapeutics. 2018; 103(5), 778–786.
25.Bienfait, k., Aparna Chhibber, Jean-Claude
Marshall, Martin Armstrong, Charles Cox, Peter
M.Shaw & Charles Paulding. Current challenges and
opportunities for pharmacogenomics: perspective of the
Industry Pharmacogenomics Working Group (I-PWG).
HumanGenetics. 2022;141. P1165–1173.
26.Cecchin, E., and Gabriele Stocco. Pharmacogenomics
and Personalized Medicine. Genes.2020; 11(6), 679.
27.Guy, J. W., Patel, I., & Oestreich, J. H. Clinical
Application and Educational Training for
Pharmacogenomics. Pharmacy. 2020; 8(3), 163.
28.Nickola, T. J., Green, J. S., Harralson, A. F., & Obrien,
T. J. The current and future state of pharmacogenomics
medical education in the USA. Pharmacogenomics.
2012; 13(12), 1419–1425.
29.Latif, D. A., & McKay, A. B. Pharmacogenetics and
pharmacogenomics instruction in colleges and schools
of pharmacy in the United States. American Journal of
Pharmaceutical Education. 2005; 69(2), 152–156.
30.Zayts, O., & Luo, Z. Commodification and
marketisation of genetic testing through online direct-
to-consumer platforms in Hong Kong. Discourse and
Communication. 2017; 11(6), 630–647.
31.Rafiq, M., Ianuale, C., Ricciardi, W., & Boccia, S.
Direct-to-consumer genetic testing: A systematic review
of european guidelines, recommendations, and position
statements. Genetic Testing and Molecular Biomarkers.
2015; 19(10), 535–547.
32.Campion, M. A., Goldgar, C., Hopkin, R. J., Prows,
C. A., & Dasgupta, S. Genomic education for the
next generation of health-care providers. Genetics in
Medicine. 2019; 21(11), 2422–2430.
33.Learning, K., & Curriculum, A. Science Education.
Physics Today. 1964; 17(11), 94.
34.Hunt, S., Wisocki, P., & Yanko, J. Worry and use of
coping strategies among older and younger adults.
Journal of Anxiety Disorders. 2003; 17(5), 547–560.
35.Chang, E. C. a Test of a General Negativity Hypothesis.
1996; 21(5), 819–822.
36.Brookfield, S. from the SAGE Social Science
Collections . All Rights. Hispanic Journal of Behavioral
Sciences. 1984; 9(2), 183–205.
37.Winkler, E. C., & Wiemann, S. Findings made in gene
panel to whole genome sequencing: data, knowledge,
ethics–and consequences? Expert Review of Molecular
Diagnostics. 2016; 16(12), 1259–1270.
Nashrifa Israt Khanomet al Pers M J24
38.Howard, H. C., & Borry, P. Survey of European clinical
geneticists on awareness, experiences and attitudes
towards direct-to-consumer genetic testing. Genome
Medicine.2013; 5(5), 0–31.